NEU 0.00% $19.97 neuren pharmaceuticals limited

Ann: 2023 Annual Report to shareholders, page-143

  1. 100 Posts.
    lightbulb Created with Sketch. 125
    "In twelve months this should see a share price at approximately $50. A takeover at that time, with risks reduced and future potential identifiable then a healthy premium takeover towards $150 is not unreasonable."
    Given that Neuren, post FDA approval, is now trading at a price around the same as after successful phase 2 results, why would a buyer pay a 300% premium?
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$19.97
Change
0.000(0.00%)
Mkt cap ! $2.552B
Open High Low Value Volume
$19.96 $19.97 $19.69 $4.156M 209.6K

Buyers (Bids)

No. Vol. Price($)
1 246 $19.88
 

Sellers (Offers)

Price($) Vol. No.
$19.99 512 1
View Market Depth
Last trade - 16.10pm 05/07/2024 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.